| Ytd | -80.71% | |
| 1y | -57.89% |
| Open | 3.46 | Prev Close | 3.46 | Low | 3.27 | High | 3.46 | Mkt Cap | 646.32M |
| Vol | 2.25M | Avg Vol | 3.09M | EPS | -1.08 | P/E | N/A | Forward P/E | -4.33 |
| Beta | -1.43 | Short Ratio | 5.75 | Inst. Own | 85.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 4.69 | 200-d Avg | 8.30 | 1yr Est | 19.06 |
WVE News
WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report)'s share price reached a new 52-week low duri
Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking
Analysts downgraded SoundThinking, Moderna, Accelerant, Mobileye and Dow, revising their ratings and
Analysts downgraded Ryder, Warner Bros. Discovery, Arbor Realty, Pershing Square and PepsiCo; Ryder
Analysts downgraded PepsiCo, RLJ Lodging Trust, Braskem.
Analysts downgraded Nike, Comcast, Restaurant Brands.
Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold
Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; pric
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking th
Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers
Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowe
B. Riley Securities analyst Madison El-Saadi maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy
Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers
WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.34) per share which missed the anal
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmf
Wells Fargo analyst Benjamin Burnett maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight
HC Wainwright & Co. analyst Andrew S. Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a B
Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a
Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowe
Canaccord Genuity analyst Whitney Ijem maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and l
Truist Securities analyst Danielle Brill maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking t
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking th
Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, i
HC Wainwright & Co. analyst Andrew S. Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a B
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
The U.S. trade deficit in goods shrank to $87.3 billion in February from $88.6 billion in January, w
https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines
